Amitriptilina Clorhidrato may be available in the countries listed below.
Amitriptyline hydrochloride (a derivative of Amitriptyline) is reported as an ingredient of Amitriptilina Clorhidrato in the following countries:
International Drug Name Search
Atrosol may be available in the countries listed below.
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atrosol in the following countries:
International Drug Name Search
Rx Only
Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.
It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-, endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is:
Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54.
Benztropine Mesylate Injection, USP is supplied as a sterile injection for intravenous and intramuscular use. Each milliliter of the injection contains:
Benztropine Mesylate: ……….1 mg
Sodium Chloride: .……………9 mg
Water for Injection q.s.: ………1 mL
Benztropine mesylate injection possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine. In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.
For use as an adjunct in the therapy of all forms of parkinsonism.
Useful also in the control of extrapyramidal disorders (except tardive dyskinesia — see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines).
Hypersensitivity to any component of benztropine mesylate injection.
Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.
Safe use in pregnancy has not been established.
Benztropine mesylate injection may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.
When benztropine mesylate injection is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or anti-dopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate injection, in combination with phenothiazines and/or tricyclic antidepressants.
Since benztropine mesylate injection contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.
Since benztropine mesylate injection has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.
Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with benztropine mesylate injection.
The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.
Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.
Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs have been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine mesylate injection is not recommended for use in patients with tardive dyskinesia.
The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.
Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see WARNINGS).
Because of the atropine-like side effects, benztropine mesylate injection should be used with caution in pediatric patients over three years of age (see CONTRAINDICATIONS).
The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity.
Tachycardia.
Paralytic ileus, constipation, vomiting, nausea, dry mouth. If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.
Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.
Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.
Blurred vision, dilated pupils.
Urinary retention, dysuria.
Occasionally, an allergic reaction, e.g., skin rash, develops. If this cannot be controlled by dosage reduction, the medication should be discontinued.
Heat stroke, hyperthermia, fever.
To report SUSPECTED ADVERSE REACTIONS, contact American Regent, Inc. at 1-800-734-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
May be any of those seen in atropine poisoning or antihistamine overdosage: CNS depression, preceded or followed by stimulation; confusion; nervousness; listlessness; intensification of mental symptoms or toxic psychosis in patients with mental illness being treated with neuroleptic drugs (e.g., phenothiazines); hallucinations (especially visual); dizziness; muscle weakness; ataxia; dry mouth; mydriasis; blurred vision; palpitations; tachycardia; elevated blood pressure; nausea; vomiting; dysuria; numbness of fingers; dysphagia; allergic reactions, e.g., skin rash; headache; hot, dry, flushed skin; delirium; coma; shock; convulsions; respiratory arrest; anhidrosis; hyperthermia; glaucoma; constipation.
Physostigmine salicylate, 1 to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic intoxication1. A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage (contraindicated in precomatose, convulsive, or psychotic states). Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression (avoid convulsant stimulants such as picrotoxin, pentylenetetrazol, or bemegride); artificial respiration for severe respiratory depression; a local miotic for mydriasis and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.
Since there is no significant difference in onset of effect after intravenous or intramuscular injection, usually there is no need to use the intravenous route. The drug is quickly effective after either route, with improvement sometimes noticeable a few minutes after injection. In emergency situations, when the condition of the patient is alarming, 1 to 2 mL of the injection normally will provide quick relief. If the parkinsonian effect begins to return, the dose can be repeated.
Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.
The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.
As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated. Generally, older patients, and thin patients cannot tolerate large doses. Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.
In idiopathic parkinsonism, therapy may be initiated with a single daily dose of 0.5 to 1 mg at bedtime. In some patients, this will be adequate; in others 4 to 6 mg a day may be required.
In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. In highly sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary.
Some patients experience greatest relief when given the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.
The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.
When benztropine mesylate injection is started, do not terminate therapy with other antiparkinsonian agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.
Benztropine mesylate injection may be used concomitantly with carbidopa-levodopa, or with levodopa, in which case periodic dosage adjustment may be required in order to maintain optimum response.
In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day parenterally. Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much.
In acute dystonic reactions, 1 to 2 mL of the injection usually relieves the condition quickly.
When extrapyramidal disorders develop soon after initiation of treatment with neuroleptic drugs (e.g., phenothiazines), they are likely to be transient. One to 2 mg of benztropine mesylate injection two or three times a day usually provides relief within one or two days. After one or two weeks, the drug should be withdrawn to determine the continued need for it. If such disorders recur, benztropine mesylate injection can be reinstituted. Certain drug-induced extrapyramidal disorders that develop slowly may not respond to benztropine mesylate injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Benztropine Mesylate Injection, USP 1 mg per mL, is a clear, colorless solution and is supplied in boxes of 5 x 2 mL vials.
NDC 0517-0785-05.
Recommended Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
1Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. 206:1963-1965, Nov. 25, 1968.
AMERICAN
REGENT, INC.
SHIRLEY, NY 11967
Revised: December 2009
PRINCIPAL DISPLAY PANEL - 2 mL Label
NDC 0517-0785-01
BENZTROPINE
MESYLATE
INJECTION, USP
2 mg/2 mL (1 mg/mL)
2 mL SINGLE USE VIAL
FOR I.M. OR I.V. USE
Rx Only
PRINCIPAL DISPLAY PANEL - 2 mL Carton
NDC 0517-0785-05
5 x 2 mL
SINGLE USE VIALS
BENZTROPINE MESYLATE
INJECTION, USP
2 mg/2 mL (1 mg/mL)
FOR INTRAMUSCULAR OR
INTRAVENOUS USE
Rx Only
AMERICAN
REGENT, INC.
SHIRLEY, NY 11967
| BENZTROPINE MESYLATE benztropine mesylate injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA091152 | 02/04/2011 | |
| Labeler - American Regent, Inc. (622781813) |
Kenacort A Orabase may be available in the countries listed below.
Triamcinolone 16α,17α-acetonide (a derivative of Triamcinolone) is reported as an ingredient of Kenacort A Orabase in the following countries:
International Drug Name Search
Radyobarit may be available in the countries listed below.
Barium Sulfate is reported as an ingredient of Radyobarit in the following countries:
International Drug Name Search
Bicalutamida QT Farma may be available in the countries listed below.
Bicalutamide is reported as an ingredient of Bicalutamida QT Farma in the following countries:
International Drug Name Search
Héparine Choay may be available in the countries listed below.
Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Héparine Choay in the following countries:
International Drug Name Search
In the US, Trastuzumab (trastuzumab systemic) is a member of the drug class HER2 inhibitors and is used to treat Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic, Esophageal Carcinoma, Gastric Cancer and Salivary Gland Cancer.
US matches:
Rec.INN
L01XC03
0180288-69-1
C6470-H10012-N1726-O2013-S42
145532
Biological response modifier, BRM
Immunomodulator
Immunoglobulin G1 (human-mouse monoclonal rhuMab HER2-gamma1-chain antihuman p185c-erbB2receptor), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer (WHO)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
In the US, Netilmicin is a member of the drug class aminoglycosides and is used to treat Bacterial Infection and Urinary Tract Infection.
Rec.INN
J01GB07,S01AA23
0056391-56-1
C21-H41-N5-O7
475
Antibacterial: Aminoglycoside
O-3-Deoxy-4-C-methyl-3-(methylamino)-ß-L-arabinopyranosyl(1->6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-glycero-hex-4-enopyranosyl-(1->4)]-2-deoxy-N³-ethyl-L-streptamine (WHO)
(2R,3R,4S,5R)-2-[(1S,2R,3R,4S,6R)-4-Amino-3-((2S,3R)-3-amino-6-aminomethyl-3,4-dihydro-2H-pyran-2-yloxy)-6-ethylamino-2-hydroxycyclohexoxy]-5-methyl-4-methylaminotetrahydropyran-3,5-diol (IUPAC)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Isotic Ixodine may be available in the countries listed below.
Idoxuridine is reported as an ingredient of Isotic Ixodine in the following countries:
International Drug Name Search
Sinutab Mono may be available in the countries listed below.
Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Sinutab Mono in the following countries:
International Drug Name Search
Cetatrex may be available in the countries listed below.
Sumatriptan succinate (a derivative of Sumatriptan) is reported as an ingredient of Cetatrex in the following countries:
International Drug Name Search
Ultralan Tablets may be available in the countries listed below.
Fluocortolone is reported as an ingredient of Ultralan Tablets in the following countries:
International Drug Name Search
